ID   E2AK2_HUMAN             Reviewed;         551 AA.
AC   P19525; A8K3P0; D6W584; E9PC80; Q52M43; Q7Z6F6; Q9UIR4;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 2.
DT   22-JUL-2015, entry version 186.
DE   RecName: Full=Interferon-induced, double-stranded RNA-activated protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Eukaryotic translation initiation factor 2-alpha kinase 2;
DE            Short=eIF-2A protein kinase 2;
DE   AltName: Full=Interferon-inducible RNA-dependent protein kinase;
DE   AltName: Full=P1/eIF-2A protein kinase;
DE   AltName: Full=Protein kinase RNA-activated;
DE            Short=PKR;
DE            Short=Protein kinase R {ECO:0000303|PubMed:11438532};
DE   AltName: Full=Tyrosine-protein kinase EIF2AK2;
DE            EC=2.7.10.2;
DE   AltName: Full=p68 kinase;
GN   Name=EIF2AK2; Synonyms=PKR, PRKR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 101-118
RP   AND 309-325, AND INDUCTION.
RX   PubMed=1695551; DOI=10.1016/0092-8674(90)90374-N;
RA   Meurs E., Chong K., Galabru J., Thomas N.S.B., Kerr I.M.,
RA   Williams B.R.G., Hovanessian A.G.;
RT   "Molecular cloning and characterization of the human double-stranded
RT   RNA-activated protein kinase induced by interferon.";
RL   Cell 62:379-390(1990).
RN   [2]
RP   SEQUENCE REVISION.
RA   Meurs E.;
RL   Submitted (AUG-1990) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1373553; DOI=10.1016/0042-6822(92)90732-5;
RA   Thomis D.C., Doohan J.P., Samuel C.E.;
RT   "Mechanism of interferon action: cDNA structure, expression, and
RT   regulation of the interferon-induced, RNA-dependent P1/eIF-2 alpha
RT   protein kinase from human cells.";
RL   Virology 188:33-46(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=8921913; DOI=10.1016/0378-1119(96)00314-9;
RA   Kuhen K.L., Shen X., Samuel C.E.;
RT   "Mechanism of interferon action sequence of the human interferon-
RT   inducible RNA-dependent protein kinase (PKR) deduced from genomic
RT   clones.";
RL   Gene 178:191-193(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=8812437; DOI=10.1006/geno.1996.0446;
RA   Kuhen K.L., Shen X., Carlisle E.R., Richardson A.L., Weier H.-U.G.,
RA   Tanaka H., Samuel C.E.;
RT   "Structural organization of the human gene (PKR) encoding an
RT   interferon-inducible RNA-dependent protein kinase (PKR) and
RT   differences from its mouse homolog.";
RL   Genomics 36:197-201(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9726442; DOI=10.1089/jir.1998.18.609;
RA   Xu Z., Williams B.R.;
RT   "Genomic features of human PKR: alternative splicing and a polymorphic
RT   CGG repeat in the 5'-untranslated region.";
RL   J. Interferon Cytokine Res. 18:609-616(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Li H., Huang F., Shen C., Zhou G., Zheng G., Ke R., Lin L., Yang S.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-18; 27-40; 70-77; 414-426 AND 430-440, CLEAVAGE
RP   OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=Prostatic carcinoma;
RA   Bienvenut W.V., Gao M., Leug H.;
RL   Submitted (JUN-2009) to UniProtKB.
RN   [14]
RP   INTERACTION WITH DNAJC3.
RX   PubMed=8576172; DOI=10.1074/jbc.271.3.1702;
RA   Polyak S.J., Tang N., Wambach M., Barber G.N., Katze M.G.;
RT   "The P58 cellular inhibitor complexes with the interferon-induced,
RT   double-stranded RNA-dependent protein kinase, PKR, to regulate its
RT   autophosphorylation and activity.";
RL   J. Biol. Chem. 271:1702-1707(1996).
RN   [15]
RP   INTERACTION WITH HIV-1 TAT.
RX   PubMed=9079663; DOI=10.1074/jbc.272.13.8388;
RA   Brand S.R., Kobayashi R., Mathews M.B.;
RT   "The Tat protein of human immunodeficiency virus type 1 is a substrate
RT   and inhibitor of the interferon-induced, virally activated protein
RT   kinase, PKR.";
RL   J. Biol. Chem. 272:8388-8395(1997).
RN   [16]
RP   INTERACTION WITH HCV NS5A.
RX   PubMed=9143277; DOI=10.1006/viro.1997.8493;
RA   Gale M.J. Jr., Korth M.J., Tang N.M., Tan S.-L., Hopkins D.A.,
RA   Dever T.E., Polyak S.J., Gretch D.R., Katze M.G.;
RT   "Evidence that hepatitis C virus resistance to interferon is mediated
RT   through repression of the PKR protein kinase by the nonstructural 5A
RT   protein.";
RL   Virology 230:217-227(1997).
RN   [17]
RP   INTERACTION WITH INFLUENZA A NS1 PROTEIN.
RX   PubMed=9781815; DOI=10.1089/jir.1998.18.757;
RA   Tan S.L., Katze M.G.;
RT   "Biochemical and genetic evidence for complex formation between the
RT   influenza A virus NS1 protein and the interferon-induced PKR protein
RT   kinase.";
RL   J. Interferon Cytokine Res. 18:757-766(1998).
RN   [18]
RP   INTERACTION WITH HCV E2 ENVELOPE PROTEIN.
RX   PubMed=10390359; DOI=10.1126/science.285.5424.107;
RA   Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M.C.;
RT   "Inhibition of the interferon-inducible protein kinase PKR by HCV E2
RT   protein.";
RL   Science 285:107-110(1999).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH IKBKB.
RX   PubMed=10848580; DOI=10.1128/MCB.20.13.4532-4542.2000;
RA   Bonnet M.C., Weil R., Dam E., Hovanessian A.G., Meurs E.F.;
RT   "PKR stimulates NF-kappaB irrespective of its kinase function by
RT   interacting with the IkappaB kinase complex.";
RL   Mol. Cell. Biol. 20:4532-4542(2000).
RN   [20]
RP   INTERACTION WITH TARBP2.
RX   PubMed=11438532; DOI=10.1074/jbc.M103584200;
RA   Daher A., Longuet M., Dorin D., Bois F., Segeral E., Bannwarth S.,
RA   Battisti P.-L., Purcell D.F., Benarous R., Vaquero C., Meurs E.F.,
RA   Gatignol A.;
RT   "Two dimerization domains in the trans-activation response RNA-binding
RT   protein (TRBP) individually reverse the protein kinase R inhibition of
RT   HIV-1 long terminal repeat expression.";
RL   J. Biol. Chem. 276:33899-33905(2001).
RN   [21]
RP   PHOSPHORYLATION AT SER-83; THR-88; THR-89; THR-90; SER-242; THR-255
RP   AND THR-258, MUTAGENESIS OF SER-83; THR-88; THR-89; THR-90; SER-242;
RP   THR-255; THR-258 AND LYS-296, AND INHIBITION BY HCV E2 ENVELOPE
RP   PROTEIN.
RX   PubMed=11152499; DOI=10.1128/JVI.75.3.1265-1273.2001;
RA   Taylor D.R., Tian B., Romano P.R., Hinnebusch A.G., Lai M.M.C.,
RA   Mathews M.B.;
RT   "Hepatitis C virus envelope protein E2 does not inhibit PKR by simple
RT   competition with autophosphorylation sites in the RNA-binding
RT   domain.";
RL   J. Virol. 75:1265-1273(2001).
RN   [22]
RP   MUTAGENESIS, AND PHOSPHORYLATION AT THR-446 AND THR-451.
RX   PubMed=11337501; DOI=10.1074/jbc.M102108200;
RA   Zhang F., Romano P.R., Nagamura-Inoue T., Tian B., Dever T.E.,
RA   Mathews M.B., Ozato K., Hinnebusch A.G.;
RT   "Binding of double-stranded RNA to protein kinase PKR is required for
RT   dimerization and promotes critical autophosphorylation events in the
RT   activation loop.";
RL   J. Biol. Chem. 276:24946-24958(2001).
RN   [23]
RP   INTERACTION WITH HHV-8 PROTEIN VIRF2.
RX   PubMed=11160738; DOI=10.1128/JVI.75.5.2345-2352.2001;
RA   Burysek L., Pitha P.M.;
RT   "Latently expressed human herpesvirus 8-encoded interferon regulatory
RT   factor 2 inhibits double-stranded RNA-activated protein kinase.";
RL   J. Virol. 75:2345-2352(2001).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH HHV-1 US11.
RX   PubMed=11836380; DOI=10.1128/jvi.76.5.2029-2035.2002;
RA   Cassady K.A., Gross M.;
RT   "The herpes simplex virus type 1 U(S)11 protein interacts with protein
RT   kinase R in infected cells and requires a 30-amino-acid sequence
RT   adjacent to a kinase substrate domain.";
RL   J. Virol. 76:2029-2035(2002).
RN   [25]
RP   INTERACTION WITH NPM1, AND ENZYME REGULATION.
RX   PubMed=12882984; DOI=10.1074/jbc.M301392200;
RA   Pang Q., Christianson T.A., Koretsky T., Carlson H., David L.,
RA   Keeble W., Faulkner G.R., Speckhart A., Bagby G.C.;
RT   "Nucleophosmin interacts with and inhibits the catalytic function of
RT   eukaryotic initiation factor 2 kinase PKR.";
RL   J. Biol. Chem. 278:41709-41717(2003).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH MAP2K6.
RX   PubMed=15229216; DOI=10.1074/jbc.M406554200;
RA   Silva A.M., Whitmore M., Xu Z., Jiang Z., Li X., Williams B.R.;
RT   "Protein kinase R (PKR) interacts with and activates mitogen-activated
RT   protein kinase kinase 6 (MKK6) in response to double-stranded RNA
RT   stimulation.";
RL   J. Biol. Chem. 279:37670-37676(2004).
RN   [27]
RP   IDENTIFICATION IN A COMPLEX WITH FANCA; FANCC; FANCG AND HSP70.
RX   PubMed=15299030; DOI=10.1074/jbc.M403884200;
RA   Zhang X., Li J., Sejas D.P., Rathbun K.R., Bagby G.C., Pang Q.;
RT   "The Fanconi anemia proteins functionally interact with the protein
RT   kinase regulated by RNA (PKR).";
RL   J. Biol. Chem. 279:43910-43919(2004).
RN   [28]
RP   FUNCTION, INTERACTION WITH TRAF2; TRAF5 AND TRAF6, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15121867; DOI=10.1128/MCB.24.10.4502-4512.2004;
RA   Gil J., Garcia M.A., Gomez-Puertas P., Guerra S., Rullas J.,
RA   Nakano H., Alcami J., Esteban M.;
RT   "TRAF family proteins link PKR with NF-kappa B activation.";
RL   Mol. Cell. Biol. 24:4502-4512(2004).
RN   [29]
RP   INHIBITION BY VACCINIA VIRUS PROTEIN E3.
RX   PubMed=15207627; DOI=10.1016/j.virol.2004.03.012;
RA   Langland J.O., Jacobs B.L.;
RT   "Inhibition of PKR by vaccinia virus: role of the N- and C-terminal
RT   domains of E3L.";
RL   Virology 324:419-429(2004).
RN   [30]
RP   REVIEW.
RX   PubMed=17158706; DOI=10.1128/MMBR.00027-06;
RA   Garcia M.A., Gil J., Ventoso I., Guerra S., Domingo E., Rivas C.,
RA   Esteban M.;
RT   "Impact of protein kinase PKR in cell biology: from antiviral to
RT   antiproliferative action.";
RL   Microbiol. Mol. Biol. Rev. 70:1032-1060(2006).
RN   [31]
RP   PHOSPHORYLATION AT TYR-101; TYR-162 AND TYR-293.
RX   PubMed=16373505; DOI=10.1073/pnas.0508207103;
RA   Su Q., Wang S., Baltzis D., Qu L.K., Wong A.H., Koromilas A.E.;
RT   "Tyrosine phosphorylation acts as a molecular switch to full-scale
RT   activation of the eIF2alpha RNA-dependent protein kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:63-68(2006).
RN   [32]
RP   INTERACTION WITH ADAR.
RX   PubMed=17079286; DOI=10.1128/JVI.01527-06;
RA   Nie Y., Hammond G.L., Yang J.H.;
RT   "Double-stranded RNA deaminase ADAR1 increases host susceptibility to
RT   virus infection.";
RL   J. Virol. 81:917-923(2007).
RN   [33]
RP   REVIEW ON ENZYME REGULATION.
RX   PubMed=17196820; DOI=10.1016/j.tibs.2006.12.003;
RA   Cole J.L.;
RT   "Activation of PKR: an open and shut case?";
RL   Trends Biochem. Sci. 32:57-62(2007).
RN   [34]
RP   FUNCTION, INTERACTION WITH NCK1, AND ENZYME REGULATION.
RX   PubMed=18835251; DOI=10.1016/j.bbrc.2008.09.112;
RA   Cardin E., Larose L.;
RT   "Nck-1 interacts with PKR and modulates its activation by dsRNA.";
RL   Biochem. Biophys. Res. Commun. 377:231-235(2008).
RN   [35]
RP   INTERACTION WITH DUS2L, AND ENZYME REGULATION.
RX   PubMed=18096616; DOI=10.1093/nar/gkm1129;
RA   Mittelstadt M., Frump A., Khuu T., Fowlkes V., Handy I., Patel C.V.,
RA   Patel R.C.;
RT   "Interaction of human tRNA-dihydrouridine synthase-2 with interferon-
RT   induced protein kinase PKR.";
RL   Nucleic Acids Res. 36:998-1008(2008).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83 AND SER-456, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [37]
RP   FUNCTION.
RX   PubMed=19507191; DOI=10.1002/jcp.21848;
RA   Blalock W.L., Grimaldi C., Fala F., Follo M., Horn S., Basecke J.,
RA   Martinelli G., Cocco L., Martelli A.M.;
RT   "PKR activity is required for acute leukemic cell maintenance and
RT   growth: a role for PKR-mediated phosphatase activity to regulate GSK-3
RT   phosphorylation.";
RL   J. Cell. Physiol. 221:232-241(2009).
RN   [38]
RP   FUNCTION, AND INTERACTION WITH DHX9.
RX   PubMed=19229320; DOI=10.1371/journal.ppat.1000311;
RA   Sadler A.J., Latchoumanin O., Hawkes D., Mak J., Williams B.R.;
RT   "An antiviral response directed by PKR phosphorylation of the RNA
RT   helicase A.";
RL   PLoS Pathog. 5:E1000311-E1000311(2009).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [40]
RP   FUNCTION IN HCV RESTRICTION.
RX   PubMed=19189853; DOI=10.1016/j.virusres.2009.01.007;
RA   Kang J.I., Kwon S.N., Park S.H., Kim Y.K., Choi S.Y., Kim J.P.,
RA   Ahn B.Y.;
RT   "PKR protein kinase is activated by hepatitis C virus and inhibits
RT   viral replication through translational control.";
RL   Virus Res. 142:51-56(2009).
RN   [41]
RP   FUNCTION.
RX   PubMed=20171114; DOI=10.1016/j.cyto.2010.01.008;
RA   Lin S.S., Lee D.C., Law A.H., Fang J.W., Chua D.T., Lau A.S.;
RT   "A role for protein kinase PKR in the mediation of Epstein-Barr virus
RT   latent membrane protein-1-induced IL-6 and IL-10 expression.";
RL   Cytokine 50:210-219(2010).
RN   [42]
RP   FUNCTION AS CDK1 KINASE UPON DNA DAMAGE, AND FUNCTION AS
RP   TYROSINE-PROTEIN KINASE.
RX   PubMed=20395957; DOI=10.1038/embor.2010.45;
RA   Yoon C.-H., Miah M.A., Kim K.P., Bae Y.-S.;
RT   "New Cdc2 Tyr 4 phosphorylation by dsRNA-activated protein kinase
RT   triggers Cdc2 polyubiquitination and G2 arrest under genotoxic
RT   stresses.";
RL   EMBO Rep. 11:393-399(2010).
RN   [43]
RP   FUNCTION.
RX   PubMed=21123651; DOI=10.1101/gad.1965010;
RA   Harashima A., Guettouche T., Barber G.N.;
RT   "Phosphorylation of the NFAR proteins by the dsRNA-dependent protein
RT   kinase PKR constitutes a novel mechanism of translational regulation
RT   and cellular defense.";
RL   Genes Dev. 24:2640-2653(2010).
RN   [44]
RP   FUNCTION IN HCV RESTRICTION.
RX   PubMed=19840259; DOI=10.1111/j.1478-3231.2009.02144.x;
RA   Chang J.H., Kato N., Muroyama R., Taniguchi H., Guleng B., Dharel N.,
RA   Shao R.X., Tateishi K., Jazag A., Kawabe T., Omata M.;
RT   "Double-stranded RNA-activated protein kinase inhibits hepatitis C
RT   virus replication but may be not essential in interferon treatment.";
RL   Liver Int. 30:311-318(2010).
RN   [45]
RP   FUNCTION, AND PHOSPHORYLATION AT THR-451.
RX   PubMed=20685959; DOI=10.1091/mbc.E10-06-0481;
RA   Yang X., Nath A., Opperman M.J., Chan C.;
RT   "The double-stranded RNA-dependent protein kinase differentially
RT   regulates insulin receptor substrates 1 and 2 in HepG2 cells.";
RL   Mol. Biol. Cell 21:3449-3458(2010).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [47]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [48]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION.
RX   PubMed=21029237; DOI=10.1111/j.1750-3639.2010.00437.x;
RA   Bose A., Mouton-Liger F., Paquet C., Mazot P., Vigny M., Gray F.,
RA   Hugon J.;
RT   "Modulation of tau phosphorylation by the kinase PKR: implications in
RT   Alzheimer's disease.";
RL   Brain Pathol. 21:189-200(2011).
RN   [49]
RP   REVIEW.
RX   PubMed=21924887; DOI=10.1016/j.coi.2011.08.009;
RA   Pfaller C.K., Li Z., George C.X., Samuel C.E.;
RT   "Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for
RT   old players as modulators of the interferon response.";
RL   Curr. Opin. Immunol. 23:573-582(2011).
RN   [50]
RP   REVIEW.
RX   PubMed=21166592; DOI=10.1089/jir.2010.0099;
RA   Pindel A., Sadler A.;
RT   "The role of protein kinase R in the interferon response.";
RL   J. Interferon Cytokine Res. 31:59-70(2011).
RN   [51]
RP   FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION BY MASS SPECTROMETRY,
RP   AND PHOSPHORYLATION.
RX   PubMed=21072047; DOI=10.1038/leu.2010.264;
RA   Blalock W.L., Bavelloni A., Piazzi M., Tagliavini F., Faenza I.,
RA   Martelli A.M., Follo M.Y., Cocco L.;
RT   "Multiple forms of PKR present in the nuclei of acute leukemia cells
RT   represent an active kinase that is responsive to stress.";
RL   Leukemia 25:236-245(2011).
RN   [52]
RP   FUNCTION IN HBV RESTRICTION.
RX   PubMed=21710204; DOI=10.1007/s10059-011-1059-6;
RA   Park I.H., Baek K.W., Cho E.Y., Ahn B.Y.;
RT   "PKR-dependent mechanisms of interferon-? for inhibiting hepatitis B
RT   virus replication.";
RL   Mol. Cells 32:167-172(2011).
RN   [53]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22214662; DOI=10.4161/cc.11.2.18999;
RA   Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.;
RT   "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and
RT   activation, leading to G(1) arrest.";
RL   Cell Cycle 11:407-417(2012).
RN   [54]
RP   REVIEW.
RX   PubMed=22633454; DOI=10.1016/j.immuni.2012.05.010;
RA   Lacy-Hulbert A., Stuart L.M.;
RT   "Penetration resistance: PKR's other talent.";
RL   Immunity 36:695-696(2012).
RN   [55]
RP   FUNCTION.
RX   PubMed=22948139; DOI=10.1074/jbc.M112.390039;
RA   McAllister C.S., Taghavi N., Samuel C.E.;
RT   "Protein kinase PKR amplification of interferon beta induction occurs
RT   through initiation factor eIF-2alpha-mediated translational control.";
RL   J. Biol. Chem. 287:36384-36392(2012).
RN   [56]
RP   FUNCTION, AND INTERACTION WITH STAT3.
RX   PubMed=23084476; DOI=10.1016/j.molcel.2012.09.013;
RA   Shen S., Niso-Santano M., Adjemian S., Takehara T., Malik S.A.,
RA   Minoux H., Souquere S., Marino G., Lachkar S., Senovilla L.,
RA   Galluzzi L., Kepp O., Pierron G., Maiuri M.C., Hikita H., Kroemer R.,
RA   Kroemer G.;
RT   "Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity.";
RL   Mol. Cell 48:667-680(2012).
RN   [57]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [58]
RP   FUNCTION, INTERACTION WITH NLRP1; NLRP3; NLRC4 AND AIM2, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=22801494; DOI=10.1038/nature11290;
RA   Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundbaeck P.,
RA   Valdes-Ferrer S.I., Olofsson P.S., Kalb T., Roth J., Zou Y.,
RA   Erlandsson-Harris H., Yang H., Ting J.P., Wang H., Andersson U.,
RA   Antoine D.J., Chavan S.S., Hotamisligil G.S., Tracey K.J.;
RT   "Novel role of PKR in inflammasome activation and HMGB1 release.";
RL   Nature 488:670-674(2012).
RN   [59]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [60]
RP   REVIEW.
RX   PubMed=23092889; DOI=10.1126/scisignal.2003511;
RA   Kang R., Tang D.;
RT   "PKR-dependent inflammatory signals.";
RL   Sci. Signal. 5:PE47-PE47(2012).
RN   [61]
RP   FUNCTION.
RX   PubMed=22381929; DOI=10.1016/j.virol.2012.01.029;
RA   Taghavi N., Samuel C.E.;
RT   "Protein kinase PKR catalytic activity is required for the PKR-
RT   dependent activation of mitogen-activated protein kinases and
RT   amplification of interferon beta induction following virus
RT   infection.";
RL   Virology 427:208-216(2012).
RN   [62]
RP   REVIEW.
RX   PubMed=23202496; DOI=10.3390/v4112598;
RA   Dabo S., Meurs E.F.;
RT   "dsRNA-dependent protein kinase PKR and its role in stress, signaling
RT   and HCV infection.";
RL   Viruses 4:2598-2635(2012).
RN   [63]
RP   TISSUE SPECIFICITY.
RX   PubMed=23403623; DOI=10.1182/blood-2012-09-456400;
RA   Liu X., Bennett R.L., Cheng X., Byrne M., Reinhard M.K., May W.S. Jr.;
RT   "PKR regulates proliferation, differentiation and survival of murine
RT   hematopoietic stem/progenitor cells.";
RL   Blood 121:3364-3374(2013).
RN   [64]
RP   REVIEW.
RX   PubMed=23354059; DOI=10.1007/s00018-012-1252-6;
RA   Donnelly N., Gorman A.M., Gupta S., Samali A.;
RT   "The eIF2alpha kinases: their structures and functions.";
RL   Cell. Mol. Life Sci. 70:3493-3511(2013).
RN   [65]
RP   FUNCTION, ISGYLATION AT LYS-69 AND LYS-159, AND ENZYME REGULATION.
RX   PubMed=23229543; DOI=10.1074/jbc.M112.401851;
RA   Okumura F., Okumura A.J., Uematsu K., Hatakeyama S., Zhang D.E.,
RA   Kamura T.;
RT   "Activation of double-stranded RNA-activated protein kinase (PKR) by
RT   interferon-stimulated gene 15 (ISG15) modification down-regulates
RT   protein translation.";
RL   J. Biol. Chem. 288:2839-2847(2013).
RN   [66]
RP   INTERACTION WITH TOS NSS, AND ENZYME REGULATION.
RX   PubMed=23325696; DOI=10.1128/JVI.02506-12;
RA   Kalveram B., Ikegami T.;
RT   "Toscana virus NSs protein promoftes degradation of double-stranded
RT   RNA-dependent protein kinase.";
RL   J. Virol. 87:3710-3718(2013).
RN   [67]
RP   FUNCTION IN MV RESTRICTION.
RX   PubMed=23115276; DOI=10.1128/JVI.02270-12;
RA   Okonski K.M., Samuel C.E.;
RT   "Stress granule formation induced by measles virus is protein kinase
RT   PKR dependent and impaired by RNA adenosine deaminase ADAR1.";
RL   J. Virol. 87:756-766(2013).
RN   [68]
RP   FUNCTION.
RX   PubMed=23372823; DOI=10.1371/journal.pone.0055108;
RA   Li Y., Xie J., Wu S., Xia J., Zhang P., Liu C., Zhang P., Huang X.;
RT   "Protein kinase regulated by dsRNA downregulates the interferon
RT   production in dengue virus- and dsrna-stimulated human lung epithelial
RT   cells.";
RL   PLoS ONE 8:E55108-E55108(2013).
RN   [69]
RP   FUNCTION IN HCV RESTRICTION.
RX   PubMed=23399035; DOI=10.1016/j.virol.2013.01.015;
RA   Zhang L., Alter H.J., Wang H., Jia S., Wang E., Marincola F.M.,
RA   Shih J.W., Wang R.Y.;
RT   "The modulation of hepatitis C virus 1a replication by PKR is
RT   dependent on NF-kB mediated interferon beta response in Huh7.5.1
RT   cells.";
RL   Virology 438:28-36(2013).
RN   [70]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [71]
RP   STRUCTURE BY NMR OF 1-175.
RX   PubMed=9736623; DOI=10.1093/emboj/17.18.5458;
RA   Nanduri S., Carpick B.W., Yang Y., Williams B.R.G., Qin J.;
RT   "Structure of the double-stranded RNA-binding domain of the protein
RT   kinase PKR reveals the molecular basis of its dsRNA-mediated
RT   activation.";
RL   EMBO J. 17:5458-5465(1998).
RN   [72]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 258-550 IN COMPLEX WITH
RP   EIF2ALPHA, AND PHOSPHORYLATION AT THR-446.
RX   PubMed=16179258; DOI=10.1016/j.cell.2005.06.044;
RA   Dar A.C., Dever T.E., Sicheri F.;
RT   "Higher-order substrate recognition of eIF2alpha by the RNA-dependent
RT   protein kinase PKR.";
RL   Cell 122:887-900(2005).
RN   [73]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLU-428; VAL-439 AND VAL-506.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: IFN-induced dsRNA-dependent serine/threonine-protein
CC       kinase which plays a key role in the innate immune response to
CC       viral infection and is also involved in the regulation of signal
CC       transduction, apoptosis, cell proliferation and differentiation.
CC       Exerts its antiviral activity on a wide range of DNA and RNA
CC       viruses including hepatitis C virus (HCV), hepatitis B virus
CC       (HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1).
CC       Inhibits viral replication via phosphorylation of the alpha
CC       subunit of eukaryotic initiation factor 2 (EIF2S1), this
CC       phosphorylation impairs the recycling of EIF2S1 between successive
CC       rounds of initiation leading to inhibition of translation which
CC       eventually results in shutdown of cellular and viral protein
CC       synthesis. Also phosphorylates other substrates including
CC       p53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral protein
CC       US11. In addition to serine/threonine-protein kinase activity,
CC       also has tyrosine-protein kinase activity and phosphorylates CDK1
CC       at 'Tyr-4' upon DNA damage, facilitating its ubiquitination and
CC       proteosomal degradation. Either as an adapter protein and/or via
CC       its kinase activity, can regulate various signaling pathways (p38
CC       MAP kinase, NF-kappa-B and insulin signaling pathways) and
CC       transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved in
CC       the expression of genes encoding proinflammatory cytokines and
CC       IFNs. Activates the NF-kappa-B pathway via interaction with IKBKB
CC       and TRAF family of proteins and activates the p38 MAP kinase
CC       pathway via interaction with MAP2K6. Can act as both a positive
CC       and negative regulator of the insulin signaling pathway (ISP).
CC       Negatively regulates ISP by inducing the inhibitory
CC       phosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-
CC       312' and positively regulates ISP via phosphorylation of PPP2R5A
CC       which activates FOXO1, which in turn up-regulates the expression
CC       of insulin receptor substrate 2 (IRS2). Can regulate NLRP3
CC       inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 and
CC       NLRC4 inflammasomes. Can trigger apoptosis via FADD-mediated
CC       activation of CASP8. Plays a role in the regulation of the
CC       cytoskeleton by binding to gelsolin (GSN), sequestering the
CC       protein in an inactive conformation away from actin.
CC       {ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380,
CC       ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216,
CC       ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853,
CC       ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191,
CC       ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114,
CC       ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959,
CC       ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651,
CC       ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662,
CC       ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494,
CC       ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476,
CC       ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543,
CC       ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10027}.
CC   -!- ENZYME REGULATION: Initially produced in an inactive form and is
CC       activated by binding to viral dsRNA, which causes dimerization and
CC       autophosphorylation in the activation loop and stimulation of
CC       function. ISGylation can activate it in the absence of viral
CC       infection. Can also be activated by heparin, proinflammatory
CC       stimuli, growth factors, cytokines, oxidative stress and the
CC       cellular protein PRKRA. Activity is markedly stimulated by
CC       manganese ions. Activation is blocked by the viral components HIV-
CC       1 Tat protein and large amounts of HIV-1 trans-activation response
CC       (TAR) RNA element as well as by the cellular proteins TARBP2,
CC       DUS2L, NPM1, NCK1 and ADAR. Down-regulated by Toscana virus (TOS)
CC       and Rift valley fever virus (RVFV) NSS which promote its
CC       proteasomal degradation. Inhibited by vaccinia virus protein E3,
CC       probably via dsRNA sequestering. {ECO:0000269|PubMed:12882984,
CC       ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,
CC       ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23325696}.
CC   -!- SUBUNIT: Homodimer. Interacts with STRBP (By similarity).
CC       Interacts with DNAJC3. Inhibited by direct interaction with viral
CC       proteins such as HCV E2, HCV NS5A and influenza A NS1. Activated
CC       by the interaction with HIV-1 Tat (By similarity). Forms a complex
CC       with FANCA, FANCC, FANCG and HSP70. Interacts with ADAR/ADAR1.
CC       Interacts with IRS1 (By similarity). The inactive form interacts
CC       with NCK1 and GSN. Interacts (via the kinase catalytic domain)
CC       with STAT3 (via SH2 domain), TRAF2 (C-terminus), TRAF5 (C-
CC       terminus) and TRAF6 (C-terminus). Interacts with MAP2K6,
CC       IKBKB/IKKB, NPM1, TARBP2, NLRP1, NLRP3, NLRC4 and AIM2. Interacts
CC       (via DRBM 1 domain) with DUS2L (via DRBM domain). Interacts with
CC       DHX9 (via N-terminus) and this interaction is dependent upon
CC       activation of the kinase. Interacts with human herpes simplex
CC       virus 1 (HHV-1) protein US11 in an RNA-dependent manner. The
CC       inactive form interacts with Toscana virus (TOS) NSS. Interacts
CC       with herpes virus 8 protein v-IRF2; this interaction inhibits
CC       EIF2AK2 activation. {ECO:0000250, ECO:0000269|PubMed:10390359,
CC       ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11160738,
CC       ECO:0000269|PubMed:11438532, ECO:0000269|PubMed:11836380,
CC       ECO:0000269|PubMed:12882984, ECO:0000269|PubMed:15121867,
CC       ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:15299030,
CC       ECO:0000269|PubMed:16179258, ECO:0000269|PubMed:17079286,
CC       ECO:0000269|PubMed:18096616, ECO:0000269|PubMed:18835251,
CC       ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:22801494,
CC       ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:23325696,
CC       ECO:0000269|PubMed:8576172, ECO:0000269|PubMed:9079663,
CC       ECO:0000269|PubMed:9143277, ECO:0000269|PubMed:9781815}.
CC   -!- INTERACTION:
CC       O92972:- (xeno); NbExp=2; IntAct=EBI-640775, EBI-6918883;
CC       P27958:- (xeno); NbExp=4; IntAct=EBI-640775, EBI-6904269;
CC       P06493:CDK1; NbExp=4; IntAct=EBI-640775, EBI-444308;
CC       Q7L2E3:DHX30; NbExp=3; IntAct=EBI-640775, EBI-1211456;
CC       Q96C10:DHX58; NbExp=2; IntAct=EBI-640775, EBI-744193;
CC       Q08211:DHX9; NbExp=2; IntAct=EBI-640775, EBI-352022;
CC       Q9UPY3:DICER1; NbExp=2; IntAct=EBI-640775, EBI-395506;
CC       Q27968:DNAJC3 (xeno); NbExp=5; IntAct=EBI-640775, EBI-640793;
CC       Q6P2E9:EDC4; NbExp=2; IntAct=EBI-640775, EBI-1006038;
CC       P05198:EIF2S1; NbExp=4; IntAct=EBI-640775, EBI-1056162;
CC       P56537:EIF6; NbExp=2; IntAct=EBI-640775, EBI-372243;
CC       Q8IY81:FTSJ3; NbExp=2; IntAct=EBI-640775, EBI-744088;
CC       P20639:K3L (xeno); NbExp=2; IntAct=EBI-640775, EBI-8674942;
CC       Q9HCE1:MOV10; NbExp=2; IntAct=EBI-640775, EBI-1055820;
CC       P06748:NPM1; NbExp=3; IntAct=EBI-640775, EBI-78579;
CC       Q9NUL3:STAU2; NbExp=2; IntAct=EBI-640775, EBI-722938;
CC       Q15633:TARBP2; NbExp=2; IntAct=EBI-640775, EBI-978581;
CC       Q9H0E2:TOLLIP; NbExp=2; IntAct=EBI-640775, EBI-74615;
CC       P04487:US11 (xeno); NbExp=3; IntAct=EBI-640775, EBI-6150681;
CC       Q2HR71:vIRF-2 (xeno); NbExp=2; IntAct=EBI-640775, EBI-8876177;
CC       Q9UL40:ZNF346; NbExp=2; IntAct=EBI-640775, EBI-2462313;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, perinuclear
CC       region. Note=Nuclear localization is elevated in acute leukemia,
CC       myelodysplastic syndrome (MDS), melanoma, breast, colon, prostate
CC       and lung cancer patient samples or cell lines as well as
CC       neurocytes from advanced Creutzfeldt-Jakob disease patients.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P19525-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P19525-2; Sequence=VSP_046177;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in thymus, spleen and bone
CC       marrow compared to non-hematopoietic tissues such as small
CC       intestine, liver, or kidney tissues. Colocalizes with GSK3B and
CC       TAU in the Alzheimer disease (AD) brain. Elevated levels seen in
CC       breast and colon carcinomas,and which correlates with tumor
CC       progression and invasiveness or risk of progression.
CC       {ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:23403623}.
CC   -!- INDUCTION: By type I interferons. {ECO:0000269|PubMed:1695551}.
CC   -!- PTM: Autophosphorylated on several Ser, Thr and Tyr residues.
CC       Autophosphorylation of Thr-451 is dependent on Thr-446 and is
CC       stimulated by dsRNA binding and dimerization. Autophosphorylation
CC       apparently leads to the activation of the kinase. Tyrosine
CC       autophosphorylation is essential for efficient dsRNA-binding,
CC       dimerization, and kinase activation. {ECO:0000269|PubMed:11152499,
CC       ECO:0000269|PubMed:11337501, ECO:0000269|PubMed:16179258,
CC       ECO:0000269|PubMed:16373505, ECO:0000269|PubMed:20685959,
CC       ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:21072047}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 2 DRBM (double-stranded RNA-binding) domains.
CC       {ECO:0000255|PROSITE-ProRule:PRU00266}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/prkr/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EIF2AK2ID41866ch2p22.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M35663; AAA36409.1; -; mRNA.
DR   EMBL; M85294; AAA18253.1; -; mRNA.
DR   EMBL; U50648; AAC50768.1; -; Genomic_DNA.
DR   EMBL; U50634; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50635; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50636; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50637; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50638; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50639; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50640; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50641; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50642; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50643; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50644; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50645; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50646; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; U50647; AAC50768.1; JOINED; Genomic_DNA.
DR   EMBL; AF167472; AAF13156.1; -; Genomic_DNA.
DR   EMBL; AF167460; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167462; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167463; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167464; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167465; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167466; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167468; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AF167470; AAF13156.1; JOINED; Genomic_DNA.
DR   EMBL; AY302136; AAP57628.1; -; mRNA.
DR   EMBL; AK290655; BAF83344.1; -; mRNA.
DR   EMBL; AK313818; BAG36554.1; -; mRNA.
DR   EMBL; AY228338; AAO38055.1; -; Genomic_DNA.
DR   EMBL; AC007899; AAY24317.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00407.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00408.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00409.1; -; Genomic_DNA.
DR   EMBL; BC093676; AAH93676.1; -; mRNA.
DR   EMBL; BC101475; AAI01476.1; -; mRNA.
DR   CCDS; CCDS1786.1; -. [P19525-1]
DR   CCDS; CCDS46259.1; -. [P19525-2]
DR   PIR; JC5225; JC5225.
DR   RefSeq; NP_001129123.1; NM_001135651.2. [P19525-1]
DR   RefSeq; NP_001129124.1; NM_001135652.2. [P19525-2]
DR   RefSeq; NP_002750.1; NM_002759.3. [P19525-1]
DR   RefSeq; XP_011531289.1; XM_011532987.1. [P19525-1]
DR   UniGene; Hs.131431; -.
DR   PDB; 1QU6; NMR; -; A=1-170.
DR   PDB; 2A19; X-ray; 2.50 A; B/C=258-538.
DR   PDB; 2A1A; X-ray; 2.80 A; B=258-538.
DR   PDB; 3UIU; X-ray; 2.90 A; A/B=254-551.
DR   PDBsum; 1QU6; -.
DR   PDBsum; 2A19; -.
DR   PDBsum; 2A1A; -.
DR   PDBsum; 3UIU; -.
DR   ProteinModelPortal; P19525; -.
DR   SMR; P19525; 1-170, 257-541.
DR   BioGrid; 111596; 82.
DR   DIP; DIP-2657N; -.
DR   IntAct; P19525; 53.
DR   MINT; MINT-92415; -.
DR   STRING; 9606.ENSP00000233057; -.
DR   BindingDB; P19525; -.
DR   ChEMBL; CHEMBL5785; -.
DR   GuidetoPHARMACOLOGY; 2016; -.
DR   PhosphoSite; P19525; -.
DR   BioMuta; EIF2AK2; -.
DR   DMDM; 125527; -.
DR   MaxQB; P19525; -.
DR   PaxDb; P19525; -.
DR   PRIDE; P19525; -.
DR   DNASU; 5610; -.
DR   Ensembl; ENST00000233057; ENSP00000233057; ENSG00000055332.
DR   Ensembl; ENST00000395127; ENSP00000378559; ENSG00000055332.
DR   Ensembl; ENST00000405334; ENSP00000385014; ENSG00000055332. [P19525-2]
DR   GeneID; 5610; -.
DR   KEGG; hsa:5610; -.
DR   UCSC; uc010fac.3; human. [P19525-1]
DR   CTD; 5610; -.
DR   GeneCards; GC02M037326; -.
DR   HGNC; HGNC:9437; EIF2AK2.
DR   HPA; CAB003845; -.
DR   HPA; HPA019795; -.
DR   MIM; 176871; gene.
DR   neXtProt; NX_P19525; -.
DR   PharmGKB; PA33779; -.
DR   eggNOG; COG0515; -.
DR   GeneTree; ENSGT00530000062984; -.
DR   HOGENOM; HOG000234351; -.
DR   HOVERGEN; HBG051430; -.
DR   InParanoid; P19525; -.
DR   KO; K16195; -.
DR   OMA; ELLYICP; -.
DR   OrthoDB; EOG71VSSK; -.
DR   PhylomeDB; P19525; -.
DR   TreeFam; TF317576; -.
DR   Reactome; REACT_115831; ISG15 antiviral mechanism.
DR   Reactome; REACT_6350; Inhibition of PKR.
DR   SignaLink; P19525; -.
DR   ChiTaRS; EIF2AK2; human.
DR   EvolutionaryTrace; P19525; -.
DR   GeneWiki; Protein_kinase_R; -.
DR   GenomeRNAi; 5610; -.
DR   NextBio; 13635839; -.
DR   PMAP-CutDB; P19525; -.
DR   PRO; PR:P19525; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; P19525; -.
DR   CleanEx; HS_EIF2AK2; -.
DR   ExpressionAtlas; P19525; baseline and differential.
DR   Genevisible; P19525; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005840; C:ribosome; TAS:AgBase.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI.
DR   GO; GO:0004694; F:eukaryotic translation initiation factor 2alpha kinase activity; TAS:ProtInc.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0008601; F:protein phosphatase type 2A regulator activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0000186; P:activation of MAPKK activity; IMP:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IEA:Ensembl.
DR   GO; GO:0030683; P:evasion or tolerance by virus of host immune response; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0019048; P:modulation by virus of host morphology or physiology; TAS:Reactome.
DR   GO; GO:0019054; P:modulation by virus of host process; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0033689; P:negative regulation of osteoblast proliferation; IMP:UniProtKB.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IMP:UniProtKB.
DR   GO; GO:0032722; P:positive regulation of chemokine production; ISS:UniProtKB.
DR   GO; GO:0001819; P:positive regulation of cytokine production; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:1901532; P:regulation of hematopoietic progenitor cell differentiation; ISS:UniProtKB.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; ISS:UniProtKB.
DR   GO; GO:1902033; P:regulation of hematopoietic stem cell proliferation; ISS:UniProtKB.
DR   GO; GO:1900225; P:regulation of NLRP3 inflammasome complex assembly; ISS:UniProtKB.
DR   GO; GO:0034047; P:regulation of protein phosphatase type 2A activity; TAS:GOC.
DR   GO; GO:0010998; P:regulation of translational initiation by eIF2 alpha phosphorylation; TAS:GOC.
DR   GO; GO:0035455; P:response to interferon-alpha; IDA:UniProtKB.
DR   GO; GO:0009615; P:response to virus; IMP:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0006412; P:translation; IEA:Ensembl.
DR   GO; GO:0019058; P:viral life cycle; TAS:Reactome.
DR   Gene3D; 3.30.160.20; -; 2.
DR   InterPro; IPR014720; dsRNA-bd_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00035; dsrm; 2.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00358; DSRM; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50137; DS_RBD; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Antiviral defense;
KW   ATP-binding; Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Host-virus interaction; Immunity; Innate immunity; Isopeptide bond;
KW   Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; RNA-binding;
KW   Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:22223895,
FT                                ECO:0000269|PubMed:22814378,
FT                                ECO:0000269|Ref.13}.
FT   CHAIN         2    551       Interferon-induced, double-stranded RNA-
FT                                activated protein kinase.
FT                                /FTId=PRO_0000085945.
FT   DOMAIN        9     77       DRBM 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00266}.
FT   DOMAIN      100    167       DRBM 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00266}.
FT   DOMAIN      267    538       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REPEAT      331    343       1.
FT   REPEAT      345    357       2.
FT   NP_BIND     273    281       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      266    551       Interaction with TRAF5.
FT   REGION      331    357       2 X 13 AA approximate repeats.
FT   ACT_SITE    414    414       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     296    296       ATP.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000269|PubMed:22223895,
FT                                ECO:0000269|PubMed:22814378,
FT                                ECO:0000269|Ref.13}.
FT   MOD_RES      83     83       Phosphoserine.
FT                                {ECO:0000269|PubMed:11152499,
FT                                ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES      88     88       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000305|PubMed:11152499}.
FT   MOD_RES      89     89       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000305|PubMed:11152499}.
FT   MOD_RES      90     90       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000305|PubMed:11152499}.
FT   MOD_RES     101    101       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16373505}.
FT   MOD_RES     162    162       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16373505}.
FT   MOD_RES     242    242       Phosphoserine; by autocatalysis.
FT                                {ECO:0000305|PubMed:11152499}.
FT   MOD_RES     255    255       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000305|PubMed:11152499}.
FT   MOD_RES     258    258       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000305|PubMed:11152499}.
FT   MOD_RES     293    293       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16373505}.
FT   MOD_RES     446    446       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11337501,
FT                                ECO:0000269|PubMed:16179258}.
FT   MOD_RES     451    451       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11337501,
FT                                ECO:0000269|PubMed:20685959}.
FT   MOD_RES     456    456       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   CROSSLNK     69     69       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ISG15).
FT   CROSSLNK    159    159       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ISG15).
FT   VAR_SEQ     263    303       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_046177.
FT   VARIANT     428    428       V -> E (in dbSNP:rs56219559).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040474.
FT   VARIANT     439    439       L -> V (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040475.
FT   VARIANT     506    506       I -> V (in dbSNP:rs34821155).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040476.
FT   MUTAGEN      59     60       SK->AA: In FL-PKR-2AI; moderate loss of
FT                                activity but no effect on dsRNA binding.
FT                                {ECO:0000269|PubMed:11337501}.
FT   MUTAGEN      60     60       K->A: Impairs dsRNA binding but not
FT                                dimerization or activity.
FT                                {ECO:0000269|PubMed:11337501}.
FT   MUTAGEN      67     67       A->E: Significant loss of activity; loss
FT                                of dsRNA binding and dimerization.
FT                                {ECO:0000269|PubMed:11337501}.
FT   MUTAGEN      83     83       S->A: No effect on enzymatic activity;
FT                                when associated with A-88; A-89 and A-90.
FT                                {ECO:0000269|PubMed:11152499}.
FT   MUTAGEN      88     88       T->A: No effect on enzymatic activity;
FT                                when associated with A-83; A-89 and A-90.
FT                                {ECO:0000269|PubMed:11152499}.
FT   MUTAGEN      89     89       T->A: No effect on enzymatic activity;
FT                                when associated with A-83; A-88 and A-90.
FT                                {ECO:0000269|PubMed:11152499}.
FT   MUTAGEN      90     90       T->A: No effect on enzymatic activity;
FT                                when associated with A-83; A-88 and A-89.
FT                                {ECO:0000269|PubMed:11152499}.
FT   MUTAGEN     149    150       TK->AA: In FL-PKR-2AII; no effect on
FT                                activity. {ECO:0000269|PubMed:11337501}.
FT   MUTAGEN     242    242       S->A: Moderate loss of activity; when
FT                                associated with A-255 and A-258.
FT                                {ECO:0000269|PubMed:11152499}.
FT   MUTAGEN     244    296       Missing: Loss of activity.
FT                                {ECO:0000269|PubMed:11337501}.
FT   MUTAGEN     255    255       T->A: Moderate loss of activity; when
FT                                associated with A-242 and A-255.
FT                                {ECO:0000269|PubMed:11152499}.
FT   MUTAGEN     258    258       T->A: Moderate loss of activity.
FT                                {ECO:0000269|PubMed:11152499}.
FT   MUTAGEN     296    296       K->R: Loss of activity.
FT                                {ECO:0000269|PubMed:11152499}.
FT   MUTAGEN     446    446       T->A: Significant loss of activity and
FT                                impairs autophosphorylation of T-451.
FT                                {ECO:0000269|PubMed:11337501}.
FT   MUTAGEN     451    451       T->A: Loss of activity.
FT                                {ECO:0000269|PubMed:11337501}.
FT   CONFLICT    102    102       I -> M (in Ref. 7; AAP57628).
FT                                {ECO:0000305}.
FT   CONFLICT    224    224       S -> R (in Ref. 7; AAP57628).
FT                                {ECO:0000305}.
FT   CONFLICT    512    512       K -> E (in Ref. 6; AAF13156).
FT                                {ECO:0000305}.
FT   STRAND        5      7       {ECO:0000244|PDB:1QU6}.
FT   HELIX        10     21       {ECO:0000244|PDB:1QU6}.
FT   STRAND       26     32       {ECO:0000244|PDB:1QU6}.
FT   TURN         35     37       {ECO:0000244|PDB:1QU6}.
FT   STRAND       41     50       {ECO:0000244|PDB:1QU6}.
FT   STRAND       54     56       {ECO:0000244|PDB:1QU6}.
FT   HELIX        61     76       {ECO:0000244|PDB:1QU6}.
FT   HELIX       102    111       {ECO:0000244|PDB:1QU6}.
FT   STRAND      115    123       {ECO:0000244|PDB:1QU6}.
FT   STRAND      125    138       {ECO:0000244|PDB:1QU6}.
FT   STRAND      144    149       {ECO:0000244|PDB:1QU6}.
FT   HELIX       150    167       {ECO:0000244|PDB:1QU6}.
FT   HELIX       261    266       {ECO:0000244|PDB:2A19}.
FT   STRAND      267    274       {ECO:0000244|PDB:2A19}.
FT   STRAND      276    278       {ECO:0000244|PDB:2A19}.
FT   STRAND      281    286       {ECO:0000244|PDB:2A19}.
FT   TURN        287    289       {ECO:0000244|PDB:2A19}.
FT   STRAND      292    299       {ECO:0000244|PDB:2A19}.
FT   HELIX       303    305       {ECO:0000244|PDB:2A19}.
FT   HELIX       306    314       {ECO:0000244|PDB:2A19}.
FT   STRAND      323    332       {ECO:0000244|PDB:2A19}.
FT   STRAND      358    366       {ECO:0000244|PDB:2A19}.
FT   HELIX       374    380       {ECO:0000244|PDB:2A19}.
FT   HELIX       381    383       {ECO:0000244|PDB:2A19}.
FT   HELIX       388    407       {ECO:0000244|PDB:2A19}.
FT   STRAND      410    412       {ECO:0000244|PDB:2A1A}.
FT   HELIX       417    419       {ECO:0000244|PDB:2A19}.
FT   STRAND      420    424       {ECO:0000244|PDB:2A19}.
FT   STRAND      427    430       {ECO:0000244|PDB:2A19}.
FT   STRAND      437    440       {ECO:0000244|PDB:2A19}.
FT   HELIX       457    461       {ECO:0000244|PDB:2A19}.
FT   HELIX       468    482       {ECO:0000244|PDB:2A19}.
FT   HELIX       488    499       {ECO:0000244|PDB:2A19}.
FT   STRAND      505    507       {ECO:0000244|PDB:3UIU}.
FT   HELIX       509    518       {ECO:0000244|PDB:2A19}.
FT   HELIX       523    525       {ECO:0000244|PDB:2A19}.
FT   HELIX       529    538       {ECO:0000244|PDB:2A19}.
SQ   SEQUENCE   551 AA;  62094 MW;  815AD83ACAB45DA3 CRC64;
     MAGDLSAGFF MEELNTYRQK QGVVLKYQEL PNSGPPHDRR FTFQVIIDGR EFPEGEGRSK
     KEAKNAAAKL AVEILNKEKK AVSPLLLTTT NSSEGLSMGN YIGLINRIAQ KKRLTVNYEQ
     CASGVHGPEG FHYKCKMGQK EYSIGTGSTK QEAKQLAAKL AYLQILSEET SVKSDYLSSG
     SFATTCESQS NSLVTSTLAS ESSSEGDFSA DTSEINSNSD SLNSSSLLMN GLRNNQRKAK
     RSLAPRFDLP DMKETKYTVD KRFGMDFKEI ELIGSGGFGQ VFKAKHRIDG KTYVIKRVKY
     NNEKAEREVK ALAKLDHVNI VHYNGCWDGF DYDPETSDDS LESSDYDPEN SKNSSRSKTK
     CLFIQMEFCD KGTLEQWIEK RRGEKLDKVL ALELFEQITK GVDYIHSKKL IHRDLKPSNI
     FLVDTKQVKI GDFGLVTSLK NDGKRTRSKG TLRYMSPEQI SSQDYGKEVD LYALGLILAE
     LLHVCDTAFE TSKFFTDLRD GIISDIFDKK EKTLLQKLLS KKPEDRPNTS EILRTLTVWK
     KSPEKNERHT C
//
